Synergistic antitumor activity of ST1571 and camptothecin in human cancer cells |
Kim, Mi-Ju
(Department of Biochemistry, Pusan National University school of Medicine)
Lee, Sang-Min (Department of Biochemistry, Pusan National University school of Medicine) Bae, Jae-Ho (Department of Biochemistry, Pusan National University school of Medicine) Chung, Byung-Seon (Department of Biochemistry, Pusan National University school of Medicine) Kang, Chi-Dug (Department of Biochemistry, Pusan National University school of Medicine) Kim, Sun-Hee (Department of Biochemistry, Pusan National University school of Medicine) |
1 | Hashimoto, M., S. Rao, O. Tokuno, K. Yamamoto, M. Takata, S. Takeda and H. Utsumi. 2003. DNA-PK: the major target for wortmannin-mediated radiosensitization by the inhibition of DSB repair via NHEJ pathway. J. Radiat. Res. (Tokyo) 44, 151-159 DOI ScienceOn |
2 | Kharbanda, S., Z. M. Yuan, R. Weichselbaum and D. Kufe. 1998. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318 DOI |
3 | Kano,Y., M. Akutsu, S. Tsunoda, H. Mano, Y. Honma and Y. Furukawa. 2001. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97, 1999-2007 DOI ScienceOn |
4 | Tipping, A. J., F. X. Mahon, G. Zafirides, V. Lagarde, J. M. Goldman and J. V. Melo. 2002. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 16, 2349-2357 DOI ScienceOn |
5 | Saijo, N. 2000. Preclinical and clinical trials of topoisomerase inhibitors. Ann. N Y Acad. Sci. 922, 92-99 DOI |
6 | Wang, H., X. Wang, X. Y. Zhou, D. J. Chen, G. C. Li, G. Iliakis and Y. Wang. 2002. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 62, 2483-2487 |
7 | Zhou, X. Y. and Y. Wang. 2000. Inhibition of DNA replication in camptothecin-treated cells is regulated by protein kinases. Ann. N Y Acad. Sci. 922, 355-359 DOI |
8 | Russell, J. S., K. Brady, W. E. Burgan, M. A. Cerra, K. A. Oswald, K. Camphausen and P. J. Tofilon. 2003. Gleevecmediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63, 7377-7383 |
9 | Adachi, N., S. So and H. Koyama. 2004. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J. Biol. Chem. 279, 37343-37348 DOI ScienceOn |
10 | Mukai, M., X. F. Che, T. Furukawa, T. Sumizawa, S. Aoki, X. Q. Ren, M. Haraguchi, Y. Sugimoto, M. Kobayashi, H. Takamatsu and S.Akiyama. 2003. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci. 94, 557-563 DOI ScienceOn |
11 | Mahon, F. X., F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. Reiffers, J. M. Goldman and J.V. Melo. 2003. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 DOI ScienceOn |
12 | Tauchi, T. and K. Ohyashiki. 2004. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk. Res, 28, 39-45 DOI ScienceOn |
13 | Panasci, L., J. P. Paiement, G. Christodoulopoulos, A. Belenkov, A. Malapetsa and R. Aloyz. 2001. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin. Cancer Res. 7, 454-461 |
14 | Shintani, S., M. Mihara, C. Li, Y. Nakahara, S. Hino, K.Nakashiro and H. Hamakawa. 2003. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 94, 894-900 DOI ScienceOn |
15 | Hansen, L. T., C. Lundin, T. Helleday, H. S. Poulsen, C. S. Sorensen, L. N. Petersen and M. Spang-Thomsen. 2003. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer 40, 157-164 DOI ScienceOn |
16 | Christodoulopoulos, G., C. Muller , B. Salles, R. Kazmi and L. Panasci. 1998. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res. 58, 1789-1792 |
17 | Um, J. H., J. K. Kwon, C. D. Kang, M. J., Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung and S. H. Kim. 2004. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J. Pharmacol. Exp. Ther. 311, 1062-1070 DOI ScienceOn |
18 | Zhelev, Z., R. Bakalova, H. Ohba, A. Ewis, M. Ishikawa, Y. Shinohara and Y. Baba. 2004. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). FEBS Lett. 570, 195-204 DOI ScienceOn |
19 | Kim, R. and T. Toge. 2004. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg. Today 34, 293-303 DOI ScienceOn |
20 | Pardanani, A. and A. Tefferi. 2004. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931-1939 DOI ScienceOn |
21 | Fabbro, D., S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, J. Mestan, T. O'Reilly, P. Traxler, B. Chaudhuri, H. Fretz, J. Zimmermann, T. Meyer, G. Caravatti, P. Furet and P. W. Manley. 2002. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93, 79-98 DOI ScienceOn |
22 | Slupianek, A., G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel and T. Skorski. 2002. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell Biol. 22, 4189-4201 DOI ScienceOn |
23 | Kim, S. H., J. H. Um, D. W. Kim, B.H. Kwon, D. W. Kim, B. S. Chung, C. D. Kang and S. H. Kim. 2000. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk. Res. 24, 917-925 DOI ScienceOn |
24 | Perona, R. and I. Sanchez-Perez. 2004. Control of oncogenesis and cancer therapy resistance. Br. J. Cancer 90, 573-577 DOI ScienceOn |